Arecor announces an exclusive formulation study collaboration with Lilly
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study partnership with Eli Lilly and Company (Lilly).
Arecor granted key US patent
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the grant by the United States Patent and Trademark Office of US Utility Patent No. 10,925,965 B2, a patent that contributes to the Company’s global patent portfolio underpinning its ArestatTM technology platform.
Arecor receives £2.8 million grant award from Innovate UK
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.
Arecor’s partner Inhibrx exercises its option to license a new formulation
Arecor Ltd , the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™.
Arecor announces publication of Phase I data for AT247 in diabetes care
Arecor Limited,, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.
First patient dosed in Phase I clinical trial of Arecor insulin candidate, AT278, for diabetes
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces dosing of the first patient in a Phase I clinical trial for its second clinical stage product, an ultra-concentrated rapid acting insulin, AT278.
Hikma and Arecor expand collaboration to develop and commercialise ready-to-administer medicine
Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.
Arecor presents at EASD 2020
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I study investigating the PD, PK and safety of AT247 in comparison to insulin aspart,NovoRapid®,and fast insulin aspart, Fiasp®, has been selected for oral presentation at the upcoming European Association for the Study of Diabetes (EASD) virtual…
ARECOR presents positive results for the first Phase I clinical trial of novel insulin formulation
AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®.
Arecor announces oral presentation of first Phase I clinical trial of novel insulin formulation
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting.
Arecor extends multi-product collaboration with clinical stage biotech
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has extended its multi-product collaboration with a US-based clinical stage biotechnology company. Under the collaboration, Arecor will leverage its Arestat™ technology to develop liquid formulations of two proprietary novel products in oncology and a rare genetic orphan…
Arecor achieves second licence milestone payment from global pharmaceutical partner
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
Arecor signs a new feasibility study agreement with top five pharma company
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical partner will fund the feasibility study and has an exclusive option to a global royalty bearing licence to the new formulation and Arecor’s associated Intellectual Property.
Arecor participates at PEPTalk 2020's Protein Science Week in San Diego, CA, USA
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA next week (20-24 January 2020).
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology
Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc.
Arecor announces positive headline results for first Phase I clinical trial of AT247, a novel formulation of insulin
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.
Arecor CEO presents at 6th China Healthcare Summit 2019 in Shanghai
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at the sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.
Arecor strengthens management team to accelerate partnership opportunities
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
Arecor and JDRF sign a joint research, development and commercialisation agreement
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organisation funding type 1 diabetes (T1D) research.
Arecor welcomes discussion with Mrs Kemi Badenoch, MP For Saffron Walden
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.
Arecor signs a new formulation evaluation agreement with an existing partner, a major global pharmaceutical company
Arecor Ltd , the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
First patient dosing in Phase I clinical trial of Arecor’s product candidate for diabetes
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
Arecor signs new multi-product collaboration with major global pharmaceutical company
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, Arestat(TM), to develop superior treatments for a range of disease areas including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.
Arecor receives regulatory approval to initiate Phase I clinical trial for insulin product
Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (CTA) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for…
Arecor appoints Chief Financial Officer
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.